The University of Debrecen Brings Hungarian Patients in to Clinerion’s Patient Network Explorer
Clinerion expands into Hungary by adding the University of Debrecen to its international patient network. The university offers clinical trial study sites with knowledge in a variety of therapeutic areas.
The University of Debrecen, Clinical Center, has a reputation for clinical research, currently running over 360 trials, with 113 starting in 2018, alone. The University is a “Global Prime Site” for IQVIA, a site for Sanofi, and has partnership with several CROs, pharma companies (incl. Pfizer, Novartis, ICON, Parexel).
The University services over 56,000 patients in Debrecen Hungary. It has study sites dedicated to many therapeutic areas, including anesthesiology and intensive care, internal medicine, dermatology, pediatrics, cardiology, neurology, oncology, orthopedics, pathology, psychiatry, pulmonology, rheumatology, surgery, ophthalmology, obstetrics and gynecology, and urology. All activities are overseen by the University’s Coordination Center for Drug Development.
“The primary mission of the Coordination Center for Drug Development is to strategically and operationally support clinical trials to be implemented at the University of Debrecen,” says Prof. Dr. Dénes Páll, M.D., PhD, Director of the center. “We aim to foster collaborative relationships with all study Sponsors and to develop future key and strategic partnerships with all current and potential partners based on professionalism and mutual benefit. We are committed to sharing relevant knowledge about clinical trials with patients, their family members, and the public in general, as well as other healthcare professionals to promote the added value of personal participation in such trials. Additionally, we focus attention on the implementation of initiatives coming from individual sites and principal investigators concerning improving efficacy, efficiency and patient centricity of the clinical trial process.”
The University of Debrecen will have a higher profile with sponsors and gain participation in international trials of leading-edge medications by being visible on Clinerion’s Patient Network Explorer platform. Patients at the university will gain access to leading-edge medical treatments as a result.
“We are very pleased to bring treatments and medicines to patients in Hungary faster, and also allowing clinical studies in the country to be more efficient,” says Ian Rentsch, CEO of Clinerion. “The University of Debrecen, with its wide range of therapeutic areas and deep expertise, will be a great addition to Clinerion’s global site network.”
About Clinerion
Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion's Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.
Clinerion website: www.clinerion.com
Clinerion’s Patient Network Explorer:www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer
For more information, please contact:
Le Vin Chin
Director, Head of Marketing & Communications
Clinerion Ltd
Elisabethenanlage 11, 4051 Basel, Switzerland
Tel.: +41 61 865 60 54
About University of Debrecen
The University of Debrecen, one of the oldest institutions of higher education in Hungary operated continuously in the same city. It is also one of the research universities of national excellence in the country offering the widest spectrum of educational programs in 14 faculties and 24 doctoral schools. The roots of higher education in the city reach all the way back to the 16th century and the foundation of the Reformed College of Debrecen in 1538. The College played a central role in Hungarian education and culture for centuries. Today the University of Debrecen is a leading and prominent institution of higher education in Hungary. It is not only at the forefront of Hungarian and international education but also active in the fields of research, innovation and development, and enjoys fruitful links with the business sector. The ever-changing social and economic environment demands continuous renewal from the institution and there is a constant need to adapt to new requirements. The University of Debrecen’s mission is to contribute to the education of future generations in cooperation with Hungarian and international partners, with high-quality interdisciplinary programs, and research built on versatile and practical experience.
Besides education, the institution also provides European-quality patient care with comprehensive services to fulfil its obligations in the city, county, and region and often on the national level as well. University Clinics employ 484 medical specialists and the 1,884 healthcare staff provide 491,656 nursing days annually. Completed specialist doctors’ hours are 299,364. The University operates a total of 1,710 beds which makes room for 95,210 inpatient cases annually with an average length of stay at 5.2 days. The number of outpatient cases is 869,345, nearly 50% of the 5.7 million medical treatments initiated are managed through outpatient care.
University of Debrecen, Coordination Center for Drug Development website: https://klinfarm.unideb.hu/en
For more information, please contact:
Prof. Dr. Dénes Páll
Director
University of Debrecen, Coordination Center for Drug Development
Tel.: +36 52 411-717
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
